KORU Medical Expands Senior Team to Accelerate Growth Strategy

Download as PDF

CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of two new leaders who will be responsible for key elements of the Company's growth strategy: Rob Cannon as the Company's new Vice President of Sales, and Brian Hertzog as the Company's new Vice President of BioPharma Business Development. Mr. Cannon will be responsible for U.S. sales and increasing the overall penetration of subcutaneous therapy for commercialized biopharmaceutical drugs. Mr. Hertzog will be responsible for leading biopharmaceutical business development and increasing the number of new biopharmaceutical drugs on the Freedom platform.

"KORU Medical provides the market-leading device in the specialty pharmacy channel for infusing subcutaneous immunoglobulins. Our quality, reliability, and value-added support has facilitated safe and effective infusions for tens of thousands of patients," said Linda Tharby, Chief Executive Officer. "Rob will lead our U.S. sales team to accelerate growth in our domestic core business. He brings deep expertise in specialty pharmacy, alternate site, and the plasma and biologics industry."

Ms. Tharby continued, "There is a significant unmet need for large-volume subcutaneous infusion solutions in biopharmaceuticals, both in drugs for clinical studies and commercial use. KORU Medical brings this expertise with FDA/CE mark regulatory clearance and millions of safe home infusions delivered every year. Brian will lead the development of new biopharmaceutical relationships for our novel therapies business, building upon his track record of growing innovative parenteral injection technologies, drug containers, and medication closure systems."

"Not only do Rob and Brian add impressive capabilities to the KORU Medical team, but our ability to attract top-tier talent demonstrates the growth potential of our business," finished Ms. Tharby.

Rob Cannon brings over 30 years of experience in sales across the healthcare industry. For the past 11 years, Mr. Cannon has been with McKesson, a healthcare supply chain management company specializing in providing pharmaceuticals and healthcare services across the globe. Most recently, he served as the Vice President of Strategic Accounts for McKesson Alternate Pharmacy Solutions, where he led the strategy, planning and implementation of sales, and marketing strategies focused on the specialty pharma and home infusion channel. Prior to that role, Mr. Cannon served as the Vice President, Sales for McKesson Plasma and Biologics and as the Senior Director for McKesson Alternate Site Pharmacy. Prior to McKesson, Mr. Cannon served as the Vice President, Biopharm Distribution, Procure Consulting for ProHealth Medical, a home infusion pharmacy service company. Prior to ProHealth, Mr. Cannon held roles at Roche Diagnostics, Abbott Laboratories, and Zenith Goldline Pharmaceuticals. Mr. Cannon received his Bachelor of Science degree in chemistry from Fordham University.

Brian Hertzog brings over 15 years of relevant experience in the drug delivery and medical device space to the KORU Medical team. Most recently, Mr. Hertzog served as the Business Development Manager for Nemera, a diversified drug delivery company, where he directly managed a broad drug delivery device portfolio. Before that, Mr. Hertzog served as a Senior Director, Commercial Development for Unilife, a drug delivery manufacturing company, where his team was responsible globally for customer acquisition and upstream contracting activities. In addition, Mr. Hertzog held previous commercial roles at medical devices and drug delivery firms Boston Scientific, Schott North America, and Datwyler. Mr. Hertzog received his Bachelor of Science degree in chemical engineering from Lafayette College.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

Forward Looking Statements

This press release may contain forward-looking statements that involve risks and uncertainties, identified by words such as "will." Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020, which is on file with the SEC and are available on our website at www.korumedical.com/investors and the SEC website at www.sec.gov. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law

Investor Contact:
Greg Chodaczek
347-620-7010
investor@korumedical.com

Source: KORU Medical Systems

Released November 1, 2021